Cardiac Power Output in Cardiogenic Shock Patients

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT05700617
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 1:1 Randomization to receive milrinone — DRUG
    Randomized to receive either inotropic agent: milrinone or no agent

Study Details

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

Key Dates

Start date
Jul 6, 2023
Status verified
Jul 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
5 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1:1 Randomization to Milrinone
    Milrinone will be given as a bolus dose of 50 mcg/kg. If a maintenance milrinone infusion is felt to be necessary, it will be maintained at 0.125-0.375 mcg/kg/min.
  • No Intervention: 1:1 No Intervention
    Subjects without evidence of cardiogenic shock will not receive Milrinone.

Primary Outcome Measure

Changes in invasive hemodynamics using a pulmonary artery (PA) catheter measuring mmHg [ Time Frame: Baseline and 6,12,24,36,72 Hours post-inotrope challenge. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of ChicagoChicagoIllinois60637
Carlisa Dixon
[email protected]
773-834-4337
Leila Yazdanbakhsh
[email protected]
773-834-5087

Find similar trials in Chicago, IL

By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
The University of Chicago· Chicago, IL

Related Studies